Table 1.
Demographic, health status, and medicine use of patients at baseline.
| Baseline characteristics | Total (N=190) | Shanghai (N=98) | Hainan (N=92) | P value | |
| Gender, n (%) | |||||
| Female | 60 (31.6) | 35 (35.7) | 25 (27.2) | .21 | |
| Male | 130 (68.4) | 63 (64.3) | 67 (72.8) | ||
| Age in years, mean (SD) | 67 (10) | 69 (8) | 64 (12) | .004 | |
| Diagnosed with hypertension, n (%) | 114 (60.0) | 70 (71.4) | 44 (47.8) | .001 | |
| Diagnosed with diabetes, n (%) | 49 (25.8) | 28 (28.6) | 21 (22.8) | .34 | |
| Heart disease type, n (%) | |||||
| MIa | 105 (55.3) | 47 (48.0) | 58 (63.0) | .03 | |
| Non-MI | 85 (44.7) | 51 (52.0) | 34 (37.0) | ||
| Time of diagnosis of heart disease, n (%) | |||||
| Within 1 year | 67 (35.3) | 17 (17.3) | 50 (54.3) | <.001 | |
| More than 1 year | 123 (64.7) | 81 (82.7) | 42 (45.7) | ||
| Number of cardiac medications, n (%) | |||||
| 1 | 20 (10.5) | 20 (20.4) | 0 | ||
| 2 | 37 (19.5) | 26 (26.5) | 11 (12.0) | <.001 | |
| 3 and more | 133 (70.0) | 52 (53.1) | 81 (88.0) | ||
| Medication class, n (%) | |||||
| ACEb inhibitors and ARBc | 43 (22.6) | 27 (27.6) | 16 (17.4) | .09 | |
| Antiplatelets | 152(80.0) | 67 (68.4) | 85 (92.4) | <.001 | |
| Beta-blockers | 118 (62.1) | 52 (53.1) | 66 (71.7) | .01 | |
| Aldosterone antagonists | 9 (4.7) | 0 | 9 (9.8) | .02 | |
| Statins and other lipid-lowering agents | 131 (68.9) | 59 (60.2) | 72 (78.3) | .01 | |
aMI: myocardial infarction.
bACE inhibitors: angiotensin-converting enzyme inhibitors.
cARB: angiotensin receptor blockers.